Ge Long Hui·2025-11-17 05:18Core Viewpoint - Nomura's report indicates that JD Health's Q3 performance is strong, with total revenue growing by 29% year-on-year to reach 17 billion yuan, driven by sales of pharmaceuticals, nutritional products, and medical devices [1] Group 1: Financial Performance - JD Health's total revenue for Q3 reached 17 billion yuan, representing a 29% year-on-year increase [1] - Sales of pharmaceuticals and nutritional products both grew by 30%, while medical device sales increased by approximately 15% [1] - The reported revenue exceeded Nomura's estimates by 4% [1] Group 2: Market Trends - JD Health's pharmaceutical sales benefit from the shift of prescriptions from hospitals to outpatient settings, alongside an accelerated online penetration rate for drug sales [1] - This trend is expected to continue until 2026 [1] Group 3: Earnings Forecast and Valuation - Nomura has raised JD Health's earnings forecasts for the fiscal years 2025 and 2026 by 9% and 8% respectively [1] - The "Buy" rating is maintained, with the target price increased from 72 HKD to 80 HKD, based on a 32 times adjusted price-to-earnings ratio for the fiscal year 2026 [1] - The adjustment reflects potential profitability upside due to enhanced operational leverage [1]